Global Antiallergics Drugs Market – Industry Trends and Forecast to 2030

Global Antiallergics Drugs Market, By Drug Class (Antihistamines, Corticosteroids, Epinephrine, Allergen Immunotherapy, Decongestants, Others), Allergy Type (Skin Allergy, Indoor and Outdoor Allergies, Food Allergy, Drug Allergies, Latex Allergy, Insect Allergy, Others), Dosage (Tablet, Injection, Inhalers, Eye drops, Others), Route of Administration (Oral, Intravenous, Topical, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.

Antiallergics Drugs Market Analysis and Size

Allergy shots have drawn a lot of attention in the antiallergics drugs market because they are the only treatment that alters the immune system and stops the development of new allergies. The market for antiallergics drugs is expanding due to the discovery of various types of immunotherapy, such as "sublingual immunotherapy." For instance, the U.S. Food and Drug Administration approved a pill for house dust mite sublingual immunotherapy in April 2017 to treat adult patients with allergic rhinitis brought on by house dust mites. An important aspect driving the market is the rise in the number of patients with diverse allergies.

Data Bridge Market Research analyses that the antiallergics drugs market, which is USD 27.90 billion in 2022, is expected to reach USD 44.47 billion by 2030, at a CAGR of 6.00% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Antiallergics Drugs Market Scope and Segmentation  

Market Definition

Antiallergic drugs are substances that are employed to treat allergic responses. Most of these medications work by blocking the actions of released inflammatory mediators on their target cells or by preventing the production of inflammatory mediators. Allergies are a growing group of medical issues that develop when the body's immune system reacts to an outside intruder. Allergens are chemicals that cause an allergic reaction in the immune system. Watery eyes, scratchy throat, running nose, rashes, wheezing, swelling, and breathing issues are all signs of allergies.

Antiallergics Drugs Market Dynamics

Drivers

• Rise in the prevalence of allergic reactions and allergies across the globe

The increasing incidence of allergic responses and allergies worldwide is a significant element fuelling the market's expansion for antihistamine medications. Antihistamines are used to treat seasonal allergies, motion sickness, nausea, cold and cough, and anxiety. Additionally, they are employed to treat urticaria, a form of skin allergy. These are the certain factors that propel the market growth.

• An increase in funding will drive the market growth

The research of new medicines is seeing an increase in funding worldwide due to the rise in allergic reactions. For instance, Nestlé Health Science invested EUR 40 million (USD 41 million) in July 2022 to co-develop Enterome's preclinical IL-10 inducer and work together to identify other food allergy candidates. Similarly, Aimmune Therapeutics paid Xencor USD 10 million in February 2020 to in-license an investigational biological anti-allergenic medication. Xencor gave the experimental humanized monoclonal antibody AIMab7195 an exclusive worldwide license to Aimmune Therapeutics for development and sales (originally XmAb7195). The medication was initially created to treat allergic asthma. Its ability to lower blood serum IgE and decrease IgE-producing cells is based on three different mechanisms of action. All of these elements are anticipated to drive the market.

Opportunities

• The launch of new products will act as an opportunity

The new introduction of immunotherapy medicines and the increase in approval are key drivers of the market growth. The Omalizumab add-on provided effectiveness advantages and enhanced allergen immunotherapy tolerance as of December 2021. The American FDA also authorized GSK's Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps in July 2021.

Hence, during the forecast period, segment growth is anticipated to be boosted by all of the above-mentioned variables, including product introductions and the safety and efficacy of SCIT.

Restraints/Challenges

• Risks associated with antiallergics drugs

The market for antiallergic drugs will face additional challenges during the forecast period due to the high cost of treatment and pharmaceutical side effects such as dizziness, headache, vomiting, fungal infections, blood pressure, lack of appetite, and sleep issues.

This antiallergics drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antiallergics drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Strides Pharma Science Limited stated that "Loratadine Softgel Capsules" had announced USFDA approval. The recently released item is a drug frequently used to treat allergies. Seasonal allergic rhinitis (SAR) and other upper respiratory tract allergies are treated with loratadine soft gel capsules.
• In 2021, Glenmark Pharmaceuticals Limited announced the "Ryaltris-AZ Nasal Spray" launch. In India, the recently released medication treats mild to severe allergic rhinitis. Being a market leader in the respiratory industry, Glenmark was the first to provide the branded generic version for treating allergic rhinitis in India at a competitive price.

Global Antiallergics Drugs Market Scope

The antiallergics drugs market is segmented on the basis of drug class, allergy type, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antihistamines
• Corticosteroids
• Epinephrine
• Allergen Immunotherapy
• Decongestants
• Others

 Allergy Type

• Skin Allergy
• Indoor
• Outdoor Allergies
• Food Allergy
• Drug Allergies
• Latex Allergy
• Insect Allergy
• Others

 Dosage

• Tablet
• Injection
• Inhalers
• Eye drops
• Others

Route of Administration

• Oral
• Intravenous
• Topical
• Others

 End-Users

• Clinic
• Hospital
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Antiallergics Drugs Market Regional Analysis/Insights

The antiallergics drugs market is analysed and market size insights and trends are provided by country, drug class, allergy type, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the antiallergics drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the antiallergics drugs market due to an increase in the number of allergy sufferers, high healthcare costs and a well-established healthcare sector in this area.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because the demand for immunotherapy treatments is increasing and healthcare infrastructure is developing quickly.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Antiallergics Drugs Market Share Analysis

The antiallergics drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antiallergics drugs market.

Some of the major players operating in the antiallergics drugs market are:

• Akorn, Incorporated (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Prestige Consumer Healthcare Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Almirall, S.A (Spain)
• Zenomed Healthcare Private Limited (India)
• Cadila Pharmaceuticals (India)